Baseline characteristics of 40 patients with idiopathic portal hypertension-related ascites after allo-HSCT
| Characteristic . | n (%)* . |
|---|---|
| Age, y | |
| Median | 54 |
| Range | 21-73 |
| Sex | |
| Male | 31 (78) |
| Female | 9 (22) |
| Disease type | |
| AML/MDS | 16 (40) |
| ALL | 11 (28) |
| NHL/HL/CLL | 12 (30) |
| MF | 1 (2) |
| Disease status at HSCT | |
| Chemosensitive (CR/PR) | 34 (85) |
| Chemorefractory (SD/PD) | 4 (10) |
| Untreated | 2 (5) |
| Prior HSCT | |
| Autologous | 1 (3) |
| Allogeneic | 2 (6) |
| Donor type | |
| Matched related | 14 (35) |
| Matched unrelated | 16 (40) |
| Haploidentical | 7 (18) |
| Umbilical cord blood | 3 (7) |
| Cell source | |
| Peripheral blood | 26 (65) |
| Bone marrow | 11 (28) |
| Umbilical cord blood | 3 (7) |
| Conditioning regimen intensity | |
| Myeloablative | 25 (63) |
| Reduced-intensity | 15 (37) |
| Conditioning regimen | |
| Flu/Mel ± other | 14 (35) |
| Flu/Bu ± other | 13 (33) |
| Flu/TBI ± other | 2 (5) |
| Bu-based | 6 (15) |
| Flu/Cy ± other | 3 (7) |
| Other | 2 (5) |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate | 25 (63) |
| Tacrolimus/MMF | 6 (15) |
| Tacrolimus/Cy ± MMF | 8 (20) |
| None | 1 (2) |
| Characteristic . | n (%)* . |
|---|---|
| Age, y | |
| Median | 54 |
| Range | 21-73 |
| Sex | |
| Male | 31 (78) |
| Female | 9 (22) |
| Disease type | |
| AML/MDS | 16 (40) |
| ALL | 11 (28) |
| NHL/HL/CLL | 12 (30) |
| MF | 1 (2) |
| Disease status at HSCT | |
| Chemosensitive (CR/PR) | 34 (85) |
| Chemorefractory (SD/PD) | 4 (10) |
| Untreated | 2 (5) |
| Prior HSCT | |
| Autologous | 1 (3) |
| Allogeneic | 2 (6) |
| Donor type | |
| Matched related | 14 (35) |
| Matched unrelated | 16 (40) |
| Haploidentical | 7 (18) |
| Umbilical cord blood | 3 (7) |
| Cell source | |
| Peripheral blood | 26 (65) |
| Bone marrow | 11 (28) |
| Umbilical cord blood | 3 (7) |
| Conditioning regimen intensity | |
| Myeloablative | 25 (63) |
| Reduced-intensity | 15 (37) |
| Conditioning regimen | |
| Flu/Mel ± other | 14 (35) |
| Flu/Bu ± other | 13 (33) |
| Flu/TBI ± other | 2 (5) |
| Bu-based | 6 (15) |
| Flu/Cy ± other | 3 (7) |
| Other | 2 (5) |
| GVHD prophylaxis | |
| Tacrolimus/methotrexate | 25 (63) |
| Tacrolimus/MMF | 6 (15) |
| Tacrolimus/Cy ± MMF | 8 (20) |
| None | 1 (2) |
Unless otherwise specified.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Bu, busulfan; CLL, chronic lymphocytic leukemia; CR, complete response; Cy, cyclophosphamide; Flu, fludarabine; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; Mel, melphalan; MF, myelofibrosis; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma; PR, partial response; PD, progressive disease; SD, stable disease; TBI, total body irradiation.